Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.26 +2.14 (3.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.12 | 52 Week High | $77.12 | |||
| Open | $61.46 | 52 Week Low | $49.03 | |||
| Day High | $63.59 | P/E | 41.08 | |||
| Day Low | $61.04 | EPS | $1.54 | |||
| Volume | 6,978,958 | |||||
